|
|
Survival
of human glioma cells treated with various combination of temozolomide and
X-rays
van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ
Department of Radiation Oncology, Academic Hospital Vrije
Universiteit, Amsterdam, The Netherlands.
radbiol@med.vu.nl
Purpose. To investigate the effect of temozolomide, a 3-methyl derivative
of mitozolomide in combination with X-rays in human glioma-derived cell
lines.
Methods
and Materials.
Glioma cell lines D384 and U251 were treated with temozolomide for various
periods of time in combinations with X-rays.
Temozolomide administration was repeated every 24 h for exposures up to 96
h.
Cytotoxicity was determined with a clonogenic assay.
Results.
Incubation of D384 cells with temozolomide during 24 h prior to or following
irradiation results in a moderate enhancement of the cytotoxicity.
Prolonged treatment with temozolomide, i.e., 48-96 h before X-rays, causes a
stronger potentiation.
In contrast, no enhancement is observed in irradiated U251 cells in combination
with 24-96 h temozolomide treatment.
In addition to single-dose irradiation, we investigated the effect of
temozolomide in D384 cells with concomitant fractionated irradiation.
A 96-h exposure to temozolomide with simultaneous doses of 2 Gy X-rays at 24-h
intervals, causes a significant further reduction in cell survival as compared
to fractionated irradiation only.
Conclusion.
Depending on the cell line, treatment of glioma cells with temozolomide and
X-rays can have either an additional effect or potentiate cell killing.
PMID: 10837964 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10837964&dopt=Abstract
|
